Paladin Energy Ltd

PDN

Paladin Energy Ltd. engages in the development and operation of uranium mines. The company is headquartered in Perth, Western Australia. The firm also owns a portfolio of uranium exploration and development assets in Canada and Australia. Its segments include Exploration, Namibia and Australia. The LHM is located in central western Namibia approximately 80 kilometers (km) east of Swakopmund and 85 km northeast of the Walvis Bay major deepwater harbor. Its Patterson Lake South (PLS) Project hosts the Triple R deposit, a large, high-grade and near-surface uranium deposit. The property comprises over 17 contiguous claims totaling 31,039 hectares. Its exploration projects include West Cluff, Larocque, Seahawk, Merlin, Corsair, Typhoon, Michelin, Manyingee and Mount Isa. The Company, through its subsidiary Aurora Energy Ltd, holds a 100% interest in over 98,320 hectares of mineral exploration licenses. These are located within the Central Mineral Belt of Labrador, Canada.

ECS Botanics Holdings Ltd

ECS

ECS Botanics Holdings Ltd. manufactures, supplies and retails cannabis products. The firm utilizes progressive and cultivation methodologies to produce medicine in a sustainable way, adopting regenerative and organic horticultural practices and renewable energy sources. The firm operates through two segments: ECS Botanics Pty Ltd (Botanics) and ECS Botanics MC Pty Ltd and Flowerday Farms Pty Ltd. Botanics is engaged in the sale of food and wellness products. ECS Botanics MC Pty Ltd and Flowerday Farms Pty Ltd are engaged in the sale of medicinal cannabis plant related products. The company specializes in cultivating cannabis, which after drying and curing, is supplied as a trimmed flower for inhalation, or extracted into resin for further formulation or manufacturing. The company cultivates a range of strains for extraction and inhalation. The company also formulates a range of off the shelf and bespoke formulations to suite needs.

Cann Group Limited

CAN

Cann Group Ltd. engages in the cultivation of medicinal cannabis and further processing into manufactured medicinal cannabis products. The company is headquartered in Melbourne, Victoria. The company went IPO on 2017-05-04. The principal activities of the Company include the cultivation of medicinal cannabis for both medicinal and research purposes pursuant to the licenses and permits issued to the group, the development and manufacture (via third party arrangements) of finished product formulations, and the pursuit and execution of various supply agreements with third parties. The company operates through cultivation of the medicinal cannabis segment. The firm supplies a range of dried flower and oil products, as well as active pharmaceutical ingredients and extracts, to customers in Australia and around the world. The company also owns Satipharm and its patent-protected capsule technology. The firm's research, cultivation, and good manufacturing practices (GMP) manufacturing facilities are in Melbourne, and a cultivation and GMP manufacturing facility is near Mildura, Victoria.

Magnis Energy Technologies Ltd

MNS

Magnis Energy Technologies Ltd. is an integrated lithium-ion battery technology and materials company, which engages in the business of exploring, developing, and mining natural flake graphite. The company is headquartered in Sydney, New South Wales and currently employs 9 full-time employees. The company went IPO on 2005-10-25. Its subsidiary, Imperium3 New York Inc. (iM3NY), operates the Lithium-ion battery plant in Endicott, New York. iM3NY has commenced commercial production of Li ion cells and accelerating its ramp-up plans to produce 15,000 cells/day up to an annual production rate of 1.8 gigawatt hours with several binding offtakes already secured. Charge CCCV’s (C4V’s) proprietary Li-ion battery technology and discoveries are known for extending battery life, greater safety and charge performance. C4V’s also provides value chain solutions for Li ion battery manufacturing through cell design and engineering, cell fabrication process, qualification of raw materials supply chain and cell fabrication equipment supplier, blueprint of plants and engaging with engineering, procurement and construction (EPC) contractors.

Syntara Limited

SNT

Syntara Ltd. is a pharmaceutical research company, which engages in the development and commercialization of healthcare products for fibrotic and inflammatory diseases. The company is headquartered in Frenchs Forest, New South Wales. The company went IPO on 2003-11-10. The firm is targeting extracellular matrix dysfunction with its amine oxidase chemistry and other technologies to develop novel medicines for blood cancers and conditions linked to inflammation and fibrosis. The Company’s lead candidate SNT-5505 is for the bone marrow cancer myelofibrosis which causes a build-up of scar tissue that leads to loss of red and white blood cells and platelets. The firm is also advancing both oral and topical pan-LOX inhibitors in scar prevention and scar modification programs. Its product candidate, SNT-4728, is an inhibitor to treat sleep disorders and slow progression of neurodegenerative diseases like Parkinson’s by reducing neuroinflammation. The Company’s other drug candidates target fibrotic and inflammatory diseases such as kidney fibrosis, NASH, pulmonary fibrosis and cardiac fibrosis.